Aimmune Therapeutics, Inc. announced that Aimmune's Chief Operating Officer Howard Raff will retire from his position on October 31, 2015. Dr. Raff will become a consultant for Aimmune, working on developing future product opportunities for food allergens.
Aimmune Therapeutics, Inc.
Equities
AIMT
US00900T1079
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.12% | 21.96B | |
-9.30% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |